EAU26 | Professor Liang-You Gu: Disitamab Vedotin Plus Immunotherapy Achieves a 1-Year DFS Rate of 97.4%, Opening New Directions for Adjuvant Treatment in High-Risk UTUC

EAU26 | Professor Liang-You Gu: Disitamab Vedotin Plus Immunotherapy Achieves a 1-Year DFS Rate of 97.4%, Opening New Directions for Adjuvant Treatment in High-Risk UTUC

With ongoing advances in research, combinations of targeted therapy and immunotherapy have become the standard first-line treatment for advanced urothelial carcinoma. However, upper tract urothelial carcinoma (UTUC) differs significantly from bladder cancer in terms of anatomical structure, pathological characteristics, prognosis, and recurrence risk. As a result, radical nephroureterectomy (RNU) remains the gold standard for non-metastatic UTUC.
ASCO GU On-site Report | Dr. Aly-Khan A. Lalani Presents CYTOSHRINK Trial Results: Early Dual Immunotherapy Combined with SBRT Shows Promise for Durable Responses in Advanced Renal Cancer

ASCO GU On-site Report | Dr. Aly-Khan A. Lalani Presents CYTOSHRINK Trial Results: Early Dual Immunotherapy Combined with SBRT Shows Promise for Durable Responses in Advanced Renal Cancer

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded. Numerous landmark studies in genitourinary oncology were presented, providing key evidence to inform and refine clinical practice. Among them, the phase II randomized CYTOSHRINK trial, focusing on treatment-naïve advanced renal cell carcinoma, reported its latest findings, offering important insights into the integration of immunotherapy with radiotherapy. We invited Professor Aly-Khan A. Lalani from the Juravinski Cancer Centre at McMaster University, Canada, to discuss the study design, clinical implications, and future directions in the field.
Voices from China at the EBMT Annual Meeting Prof. Jianping Zhang: High CD34⁺ Cell Dose Significantly Reduces EBV Reactivation and Improves Survival in Pediatric Aplastic Anemia Patients Undergoing UCBT

Voices from China at the EBMT Annual Meeting Prof. Jianping Zhang: High CD34⁺ Cell Dose Significantly Reduces EBV Reactivation and Improves Survival in Pediatric Aplastic Anemia Patients Undergoing UCBT

Pediatric aplastic anemia (AA) patients undergoing umbilical cord blood transplantation (UCBT) face outcomes that are closely tied to the infused cell dose. While recommended CD34⁺ cell doses have been established for hematologic malignancies, no clear standard exists for AA, leaving an important gap in clinical decision-making.
Voices from China at the EBMT Annual Meeting Prof. Peihua Lu / Prof. Yanli Zhao: Long-Term Outcomes of HSCT in Elderly Patients with Hematologic Malignancies—A Single-Center Comparison of Haploidentical, Matched Sibling, and Matched Unrelated Donors

Voices from China at the EBMT Annual Meeting Prof. Peihua Lu / Prof. Yanli Zhao: Long-Term Outcomes of HSCT in Elderly Patients with Hematologic Malignancies—A Single-Center Comparison of Haploidentical, Matched Sibling, and Matched Unrelated Donors

Allogeneic hematopoietic stem cell transplantation (HSCT) in elderly patients with hematologic malignancies remains associated with substantial treatment-related risks. Choosing among haploidentical, matched sibling, and matched unrelated donors remains challenging due to the lack of robust head-to-head comparative data.
Highlights from the EBMT Annual Meeting / The CAST Strategy for Heavily Pretreated Relapsed/Refractory CNS Lymphoma: A Proof-of-Concept Study

Highlights from the EBMT Annual Meeting / The CAST Strategy for Heavily Pretreated Relapsed/Refractory CNS Lymphoma: A Proof-of-Concept Study

The 52nd EBMT Annual Meeting will be held in Madrid, Spain, from March 22 to 25, 2026. As one of the most prominent international meetings in hematology, EBMT brings together experts worldwide to present advances in hematopoietic stem cell transplantation and cellular therapies, fostering innovation in clinical practice.
Highlights from the EBMT Annual Meeting Impact of the Treatment Sequence of Glofitamab and CAR-T Therapy on Efficacy, Survival, and Target Antigen Expression in Relapsed/Refractory B-NHL 

Highlights from the EBMT Annual Meeting Impact of the Treatment Sequence of Glofitamab and CAR-T Therapy on Efficacy, Survival, and Target Antigen Expression in Relapsed/Refractory B-NHL 

The 52nd EBMT Annual Meeting will take place in Madrid, Spain, from March 22 to 25, 2026. As one of the most influential international meetings in hematopoietic stem cell transplantation and cellular therapy, the congress brings together more than 6,000 experts from over 90 countries and regions to discuss advances in basic research, clinical translation, optimization of transplant strategies, and innovation in cellular therapies.
Voices from China at the EBMT Annual Meeting Prof. Xingyu Cao & Bixin Li: Efficacy and Safety of PD-1 Inhibitors in Acute Leukemia Patients with MRD Positivity After Allogeneic HSCT

Voices from China at the EBMT Annual Meeting Prof. Xingyu Cao & Bixin Li: Efficacy and Safety of PD-1 Inhibitors in Acute Leukemia Patients with MRD Positivity After Allogeneic HSCT

Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the central challenges in the treatment of acute leukemia. Minimal residual disease (MRD) positivity serves as an important early warning signal for relapse, and identifying effective interventions during this critical window has become a major focus of clinical research.
Highlights from the EBMT Annual Meeting CAR-T Alone versus CAR-T Combined with ASCT in Aggressive B-Cell Lymphoma: A Propensity Score–Matched Cohort Study 

Highlights from the EBMT Annual Meeting CAR-T Alone versus CAR-T Combined with ASCT in Aggressive B-Cell Lymphoma: A Propensity Score–Matched Cohort Study 

The 52nd EBMT Annual Meeting was held in Madrid, Spain, from March 22 to 25, 2026. As one of the leading international forums in hematology, the meeting brings together experts worldwide to present advances in transplantation, cellular immunotherapy, and complication management, and remains an important platform shaping the future of hematologic treatment.
EAU26 Afternoon Dialogue | Prof. Peng Zhang: Final Results of the HOPE-03 Study—ADC Plus Immunotherapy Opens a New Era for Bladder Preservation in MIBC

EAU26 Afternoon Dialogue | Prof. Peng Zhang: Final Results of the HOPE-03 Study—ADC Plus Immunotherapy Opens a New Era for Bladder Preservation in MIBC

The 2026 European Association of Urology Annual Congress (EAU26), held in London, brought together leading experts from across the globe to discuss the latest advances in urology. Among the highlights, the final results of the HOPE-03 study, led by Prof. Peng Zhang and his team from West China Hospital, Sichuan University, were presented as an oral session, drawing significant international attention.